Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 40% below its 5-year average of 0.04, near the low end of its 5-year range (0.00–0.08).
As of the fiscal period ended Tuesday, June 30, 2026. 1.03% below its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.03
DEBT TO EQUITY RATIO AVG 5Y
0.04
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.03%
CURRENT VS 3Y AVG
-15.58%
CURRENT VS 5Y AVG
-40.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 718 covered companies
CURRENT VS SECTOR MEDIAN
-79.44%
vs the sector median at left
Janux Therapeutics, Inc.
Market Cap
$1.03B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.03
5Y Avg
0.04
Market Cap
$1.02B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.02B
Debt to Equity Ratio
1.59
TTM Avg
4.87
3Y Avg
5.44
5Y Avg
5.44
Market Cap
$1.04B
Debt to Equity Ratio
1.94
TTM Avg
1.61
3Y Avg
1.30
5Y Avg
1.21
Market Cap
$1.04B
Debt to Equity Ratio
0.08
TTM Avg
0.07
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$1.05B
Debt to Equity Ratio
0.79
TTM Avg
0.91
3Y Avg
0.80
5Y Avg
0.56
Market Cap
$999.81M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.95M
Debt to Equity Ratio
0.23
TTM Avg
0.21
3Y Avg
0.27
5Y Avg
0.36
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $1.03B | 0.02 | 0.02 | 0.03 | 0.04 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | 0.01 | 0.01 | 0.01 | 0.01 |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.59 | 4.87 | 5.44 | 5.44 |
| Immatics N.V. (IMTX)vs › | $1.03B | 0.04 | 0.03 | 0.05 | 0.11 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 1.94 | 1.61 | 1.30 | 1.21 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 0.08 | 0.07 | 0.05 | 0.04 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 0.79 | 0.91 | 0.80 | 0.56 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $999.81M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $987.95M | 0.23 | 0.21 | 0.27 | 0.36 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.34M | 0.61 | 0.74 | 0.79 | 0.93 |
Debt/Equity
0.02
Current Ratio
16.35
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.02 |
| 2025-06-30 | 0.02 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | 0.04 |
| 2024-06-30 | 0.04 |
| 2024-03-31 | 0.04 |
| 2023-12-31 | 0.07 |
| 2023-09-30 | 0.07 |
| 2023-06-30 | 0.08 |
| 2023-03-31 | 0.08 |
| 2022-12-31 | 0.08 |
| 2022-09-30 | 0.07 |
| 2022-06-30 | 0.07 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.00 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
